As Vice President and General Manager of U.S. Surgical for Bausch + Lomb, Anthony Wallace is involved in virtually all things surgical. His day-to-day includes strategy, portfolio planning, R&D alignment, acquisitions, pricing and contracting, sales and marketing, and supply chain.On top of all that, he’s one of the key executives leading Bausch + Lomb’s five-year charge: double the number of patients reached from 2 million to 4 million.During a candid discussion with podcast host and retina surgeon Firas Rahhal, MD, Wallace discusses how current healthcare policy will affect surgical device and drug development, pricing, and patient outcomes.He also shares stories from his tenure at Novartis, including the dark time when the company called off three Beovu clinical trials due to cases of occlusive vasculitis. “It was the fastest I’ve seen any company move and it was in the name of patient safety,” he said.Listen to the podcast today to discover:The feedback Bausch + Lomb has received on Stellaris Elite for both cataract and retina procedures and how the company plans to improve on the device.Details on the Bi-Blade vitrectomy cutter and the significant upgrade Bausch + Lomb is currently testing.How Wallace identifies gap areas in surgical tools to build out the Bausch + Lomb pipeline.More details on what Wallace’s job entails as VP and GM of U.S. Surgical for Bausch.Lessons learned from nearly a decade at Novartis.An update on Bausch + Lomb’s Synergetics acquisition from 2016 and the state of the relationship after seven years together.What’s makes the retina space unique compared to other therapeutic areas.How the Inflation Reduction Act impact drug and device development, short and long term.What’s ahead for ophthalmology innovation in the next three to five years.[Press Play]